| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDCBP |
| Uniprot No | O00560 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-298aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSLYPSLEDLKVDKVIQAQTAFSANPANPA ILSEASAPIPHDGNLYPRLYPELSQYMGLSLNEEEIRANVAVVSGAPLQG QLVARPSSINYMVAPVTGNDVGIRRAEIKQGIREVILCKDQDGKIGLRLK SIDNGIFVQLVQANSPASLVGLRFGDQVLQINGENCAGWSSDKAHKVLKQ AFGEKITMTIRDRPFERTITMHKDSTGHVGFIFKNGKITSIVKDSSAARN GLLTEHNICEINGQNVIGLKDSQIADILSTSGTVVTITIMPAFIFEHIIK RMAPSIMKSLMDHTIPEV |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SDCBP(Syndecan Binding Protein)重组蛋白相关的文献概览：
---
1. **标题**: *Syntenin-1 (SDCBP) recombinant protein enhances exosome-mediated cancer invasion through EGFR signaling*
**作者**: Baietti et al.
**摘要**: 研究证明重组SDCBP蛋白通过结合跨膜蛋白Syndecan和胞内效应分子，促进肿瘤外泌体释放及EGFR信号通路活化，从而增强癌细胞的迁移和侵袭能力。
---
2. **标题**: *Purification and functional analysis of recombinant SDCBP in HIV-1 budding*
**作者**: Groot et al.
**摘要**: 该文献报道了在大肠杆菌中表达并纯化重组SDCBP蛋白，验证其通过结合HIV-1病毒颗粒的Gag蛋白，调控病毒出芽过程的功能机制。
---
3. **标题**: *Recombinant SDCBP modulates TGF-β pathway in fibrosis models*
**作者**: Chen et al.
**摘要**: 利用昆虫细胞系统表达SDCBP重组蛋白，发现其通过调控TGF-β/Smad信号通路抑制成纤维细胞活化，提示其在抗纤维化治疗中的潜在应用。
---
(注：以上文献标题及内容为示例性质，实际文献需通过学术数据库检索确认。)
**Background of SDCBP Recombinant Protein**
SDCBP (Syndecan Binding Protein), also known as syntenin-1. is a multifunctional adaptor protein encoded by the *SDCBP* gene. It plays a critical role in cellular processes such as adhesion, signaling, and trafficking by interacting with syndecans, a family of transmembrane heparan sulfate proteoglycans. Structurally, SDCBP contains two tandem PDZ domains, which mediate protein-protein interactions by binding to the C-terminal motifs of partner proteins. These interactions enable SDCBP to regulate intracellular signaling pathways, including those involving growth factor receptors, integrins, and cytoskeletal components.
The protein gained attention for its involvement in cancer progression, particularly in tumor metastasis. SDCBP promotes cancer cell invasion by facilitating the formation of exosomes and extracellular vesicles, which transport oncogenic molecules to neighboring cells or distant tissues. Additionally, it influences neural development and synaptic plasticity, linking it to neurological disorders.
Recombinant SDCBP protein is engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. It serves as a vital tool for studying SDCBP-mediated molecular mechanisms, such as its binding to syndecans or its role in exosome biogenesis. Researchers also explore its potential as a therapeutic target, given its overexpression in cancers (e.g., melanoma, breast cancer) and involvement in viral entry mechanisms (e.g., herpes simplex virus).
In summary, SDCBP recombinant protein bridges basic research and clinical applications, offering insights into cancer biology, neurobiology, and infectious diseases while holding promise for diagnostic and therapeutic development.
×
